{"id":"ibi362","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IBI362 functions as a PD-1/TGF-β bispecific antibody designed to block immune checkpoint inhibition via PD-1 while also neutralizing immunosuppressive TGF-β signaling. By targeting both pathways, the drug aims to overcome resistance to single-agent PD-1 inhibition and enhance T-cell activation and infiltration in the tumor microenvironment.","oneSentence":"IBI362 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:23.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (in development)"}]},"trialDetails":[{"nctId":"NCT07469800","phase":"PHASE3","title":"Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-04-01","conditions":"Overweight, Obesity, Hypertensive","enrollment":336},{"nctId":"NCT07083154","phase":"PHASE3","title":"GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2025-09-27","conditions":"Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes","enrollment":420},{"nctId":"NCT06184568","phase":"PHASE3","title":"A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2024-02-29","conditions":"Type 2 Diabetes, Obesity","enrollment":349},{"nctId":"NCT07255209","phase":"PHASE3","title":"A Study of IBI362 in Chinese Adolescents With Obesity or Overweight","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-12-29","conditions":"Adolescents With Obesity or Overweight With Weight-Related Comorbidities","enrollment":180},{"nctId":"NCT07000955","phase":"PHASE1, PHASE2","title":"Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-06-17","conditions":"Obesity","enrollment":98},{"nctId":"NCT06937749","phase":"PHASE2","title":"A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-07-01","conditions":"Metabolic Dysfunction-associated Steatohepatitis (MASH)","enrollment":165},{"nctId":"NCT04904913","phase":"PHASE2","title":"A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-06-08","conditions":"Overweight/ Obesity","enrollment":328},{"nctId":"NCT06536023","phase":"PHASE1","title":"This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2024-08-30","conditions":"Adolescents With Obesity","enrollment":36},{"nctId":"NCT06862908","phase":"PHASE2","title":"A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-04-01","conditions":"Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction","enrollment":141},{"nctId":"NCT06931028","phase":"PHASE3","title":"A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-06-12","conditions":"Sleep Apnea, Obstructive, Obesity","enrollment":260},{"nctId":"NCT06884293","phase":"PHASE3","title":"A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-05-09","conditions":"Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)","enrollment":470},{"nctId":"NCT05607680","phase":"PHASE3","title":"A Study of IBI362 in Participants With Obesity or Overweight","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-11-14","conditions":"Obesity Or Overweight","enrollment":610},{"nctId":"NCT06164873","phase":"PHASE3","title":"A Study of IBI362 9 mg in Chinese Adults With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-12-27","conditions":"Obesity","enrollment":462},{"nctId":"NCT05606913","phase":"PHASE3","title":"A Study of IBI362 in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-01-06","conditions":"Type 2 Diabetes","enrollment":731},{"nctId":"NCT05628311","phase":"PHASE3","title":"A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-01-06","conditions":"Type 2 Diabetes","enrollment":319},{"nctId":"NCT05793450","phase":"PHASE1","title":"Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-05-05","conditions":"Renal Impairment","enrollment":20},{"nctId":"NCT04965506","phase":"PHASE2","title":"A Study of IBI362 in Chinese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-09-06","conditions":"Type 2 Diabetes","enrollment":252},{"nctId":"NCT04440345","phase":"PHASE1, PHASE2","title":"Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-06-16","conditions":"Overweight or Obesity","enrollment":60},{"nctId":"NCT05815680","phase":"PHASE1","title":"A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-04-06","conditions":"Overweight Subjects, Obese Subjects","enrollment":48},{"nctId":"NCT04466904","phase":"PHASE1, PHASE2","title":"Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-09-12","conditions":"Type 2 Diabetes","enrollment":42},{"nctId":"NCT04773977","phase":"PHASE1","title":"Clinical Study of IBI362 in Healthy Chinese Male Subjects","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-03-03","conditions":"Overweight/Obesity","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IBI362","genericName":"IBI362","companyName":"Innovent Biologics (Suzhou) Co. Ltd.","companyId":"innovent-biologics-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IBI362 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity. Used for Non-small cell lung cancer, Other solid tumors (in development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}